How Novo Nordisk Uses Claude to Generate Clinical Study Reports in Minutes

Novo Nordisk, the global pharmaceutical company behind Ozempic, faces one of the most documentation-intensive processes in any industry. Each day of delay in bringing a new medicine to market costs up to $15 million in potential revenue.

The challenge was clinical study reports—documents up to 300 pages long required for regulatory submissions. Staff averaged just 2.3 reports per year through manual processes, making this a critical pipeline bottleneck.

Novo Nordisk built NovoScribe, an internal AI platform using Claude Code and MongoDB Atlas. The platform automates generation of regulatory-grade clinical documentation and enables non-technical team members to prototype features, producing content that regulators respond to positively.

Results were transformative: report creation dropped from 10+ weeks to 10 minutes. Device verification protocols required 95% fewer resources. The platform has expanded from clinical trials to device testing and patient materials.